Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia

Rhodococcus equi, mainly known from veterinary medicine as a pathogen in domestic animals, can also cause infections in immunocompromised humans, especially in those with defects in cellular immunity. Alemtuzumab, an anti-CD52 monoclonal antibody, causes lymphocytopenia by eliminating CD52-positive...

Full description

Bibliographic Details
Main Authors: Jan J. Meeuse, Herman G. Sprenger, Sander van Assen, Dominique Leduc, Simon M.G.J. Daenen, Jan P. Arends, Tjip S. van der Werf
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2007-12-01
Series:Emerging Infectious Diseases
Subjects:
Rhodococcus equi
Alemtuzumab
T-PLL
dispatch
the Netherlands
Online Access:https://wwwnc.cdc.gov/eid/article/13/12/06-1559_article

Internet

https://wwwnc.cdc.gov/eid/article/13/12/06-1559_article

Similar Items